Branded Legacy Subsidiary Acquires Vancouver Facility to Expand Addiction Treatment Capabilities
TL;DR
Branded Legacy's new Vancouver facility positions it to dominate addiction treatment markets with advanced manufacturing capabilities and strategic university partnerships.
The 22,000-square-foot GMP-compliant facility features ISO Class 7 and 8 clean rooms for precise development of harm reduction devices and products.
This facility directly addresses Vancouver's drug crisis by developing life-saving technologies that prevent overdoses and improve community health outcomes.
Branded Legacy's intranasal delivery technology enables precise dosing of naloxone and vaccines, revolutionizing overdose treatment and pandemic response.
Found this article helpful?
Share it with your network and spread the knowledge!
Branded Legacy, Inc. (OTC: BLEG) has announced that its subsidiary, BioLegacy Evaluative Group, has acquired a 22,000-square-foot commercial property in Vancouver, Canada, marking a significant expansion of the company's capabilities in addiction treatment and harm reduction. The new facility, which features ISO Class 7 and 8 clean rooms and complies with Good Manufacturing Practice (GMP) standards, will serve as a laboratory and manufacturing hub for developing devices and products designed to counteract hazardous substances and reduce associated harms.
The strategic location of the facility in the center of Vancouver's drug crisis enables BioLegacy to collaborate directly with affected populations while advancing technologies supported by partnerships with McMaster University and Stanford University's Dr. Eran Bendavid. This proximity to the community allows for real-time feedback and iterative development of solutions that address urgent public health needs.
Branded Legacy is a holdings company focused on health and wellness, developing innovative solutions to combat addiction by preventing overdoses and supporting recovery. The company's patented intranasal naloxone delivery device enhances accessibility and dosing precision for opioid overdose treatment, which is critical given the ongoing opioid crisis affecting communities worldwide. For more information about the company's initiatives, visit https://BrandedLegacy.com.
The acquisition of this facility represents a substantial investment in scaling up production and research capabilities, potentially accelerating the deployment of life-saving technologies. The platform also enables nasal delivery of vaccines and other medications, opening opportunities in global markets for rapid pandemic response and improved access in underserved regions. This expansion could drive shareholder value while addressing significant public health challenges.
The press release was distributed through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio. InvestorWire provides advanced wire-grade press release syndication and corporate communications solutions, ensuring broad dissemination of news to investors, influencers, and the general public. For details on their services, visit https://www.InvestorWire.com.
Curated from InvestorBrandNetwork (IBN)
